Pharmacy Group: FDA May Face Suits Over Compounding MOU

Updated Story A leading pharmacy compounding group predicts that FDA might face lawsuits from states and compounding pharmacies over its final memorandum of understanding, which subjects compounding pharmacies located in states that don’t sign the MOU to a 5% sales cap on the amount of compounded product that can be shipped out-of-state. Pharmacists and compounders say that limiting the amount of compounded drug that can be shipped to other states could cut off patient access and result...